11.03.2025 11:13:47

Arvinas, Pfizer Report Positive Topline Data From Phase 3 VERITAC-2 Study

(RTTNews) - Arvinas, Inc. (ARVN) and Pfizer Inc. (PFE) Tuesday announced positive topline results from the Phase 3 VERITAC-2 study.

The study is designed to evaluate the companies' vepdegestrant compared to AstraZeneca's fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER2-) breast cancer.

The trial met its primary goal in the estrogen receptor 1-mutant (ESR1m) population showing a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to fulvestrant. However, in the intent-to-treat (ITT) population, the study did not reach statistical significance in improvement in PFS.

Analysen zu Pfizer Inc.mehr Analysen

29.04.25 Pfizer Buy Jefferies & Company Inc.
29.04.25 Pfizer Neutral JP Morgan Chase & Co.
29.04.25 Pfizer Neutral UBS AG
14.04.25 Pfizer Buy Jefferies & Company Inc.
14.04.25 Pfizer Neutral UBS AG

Eintrag hinzufügen

Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Arvinas Inc Registered Shs 9,57 2,13% Arvinas Inc Registered Shs
Pfizer Inc. 21,41 1,83% Pfizer Inc.
pagehit